SAN FRANCISCO, Jan 13 (Reuters) - AstraZeneca has agreed to buy Boston-based Modella AI, the companies said on Tuesday, as the drug industry increases its use of artificial intelligence to accelerate the discovery of new drugs.
The companies did not disclose financial terms. In a press release, Modella AI said its "foundation models" and AI agents would be integrated into oncology research and development to support clinical development and biomarker discovery.
"Oncology drug development is becoming more complex, more data-rich and more time-sensitive," said Gabi Raia, Modella AI's chief commercial officer, adding that joining AstraZeneca would allow it to deploy its tools in global trials and clinical settings.
AstraZeneca said that this was the first acquisition of an AI firm by a big pharmaceutical company.
In an interview at the JP Morgan Healthcare Conference, AstraZeneca Chief Financial Officer Aradhana Sarin said the acquisition would "supercharge" the company's quantitative pathology and biomarker discovery efforts by bringing more data and AI capabilities in-house.
The deal was one of a number of pacts between major drug firms and AI companies that were unveiled at the healthcare conference, including a $1 billion collaboration between Nvidia and Eli Lilly. They plan to build a new research lab using Nvidia's latest-generation AI chips.
Modella will accelerate AstraZeneca’s efforts to make pathology more quantitative - using computers to analyze biopsies for relevant proteins and correlate them with clinical data - so AstraZeneca can develop “highly targeted biomarkers and then highly targeted therapeutics,” Sarin said.
The deal is an expansion of a multi-year collaboration that the companies unveiled in July.
Sarin said that partnership served as a "test drive," adding that AstraZeneca ultimately wanted Modella's data, foundation models and AI talent in-house.
She said AI tools could be used to more rapidly select patients for drug trials, which could increase the odds of clinical success and cut related costs.
(Reporting by Maggie Fick; Editing by Thomas Derpinghaus)
LATEST POSTS
- 1
6 Eyewear Brands Worth Purchasing - 2Help Your Business with Master Web based Promoting Arrangements
- 3Native artists in Texas and Mexico shared their vision of the universe for 4,000 years, ancient murals suggest
- 4Japan prepares to restart world's biggest nuclear plant, 15 years after Fukushima
- 5Former biotech CEO sued over COVID vaccine alleged insider trading
- A Concise History Of The Entertainment world
- Investigating Design and Individual Style: Track down Your Remarkable Look
- Unwinding the Starting points of America: An Excursion Through History
- Traveling Alone: An Excursion of Self-Disclosure
- The most effective method to Involve Handshakes for Compromise and Compromise
- Gym tied to outbreak of obscure disease that spreads through mist
- I served on the expert committee that advised the government on new dietary guidelines – most of our recommendations were ignored
- ‘Risk children’s lives for some extra manpower’: IRGC recruits 12 year olds to fill personnel gaps
- EU states agree first step for Ukraine reparations fund
